MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: GTCbio - Biopharmaceutical Conference
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Pradeep Nathan, Director of Neuroscience, GSK Featured at Neuro Biomarkers Meeting, September 6th-7th in Zurich - Pradeep Nathan, Director of Neuroscience at GlaxoSmithKline will give a featured presentation on ‘What is the Value of Functional Imaging in Early Clinical Development?’ at GTC’s Neurological Biomarkers conference
Pradeep Nathan, Director of Neuroscience, GSK Featured at Neuro Biomarkers Meeting, September 6th-7th in Zurich

 

NewswireToday - /newswire/ - Zurich, Switzerland, 2012/07/25 - Pradeep Nathan, Director of Neuroscience at GlaxoSmithKline will give a featured presentation on ‘What is the Value of Functional Imaging in Early Clinical Development?’ at GTC’s Neurological Biomarkers conference.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Pradeep Nathan, Director of Neuroscience at GlaxoSmithKline will give a featured presentation on ‘What is the Value of Functional Imaging in Early Clinical Development?’ at GTC’s Neurological Biomarkers conference (Sept 6th-7th, 2012 in, Switzerland)

Functional Imaging is being increasingly used in early clinical development to answer questions related to target engagement, differential efficacy and relationship with clinical outcome. However, the value of functional imaging is yet to be fully appreciated. Dr. Nathan will give examples of studies that have been done at GSK. fMRI has been used to address early clinical development questions. Dr. Nathan will outline where there is promise and where there are limitations for fMRI as a biomarker.

Professor Pradeep Nathan holds a joint appointment as Director of Neuroscience and Experimental Medicine at GlaxoSmithKline Pharmaceuticals and Lecturer in the Department of Psychiatry at Cambridge University. He is also an Adjunct Professor in the School of Psychology and Psychiatry at Monash University. Professor Nathan’s research is primarily focused on the development of translational and biological markers of neurological and psychiatric disorders, neurochemical basis of cognitive function and drug discovery. He has published over 130 peer reviewed papers and has contributed to the pre-clinical and early clinical development of a number of new drug candidates for addiction, schizophrenia, Huntington’s disease, and Alzheimer’s disease.

GTC’s Neurological Biomarkers conference is part of the 2nd Biomarkers Europe Summit and will bring together leading experts across the industry and academia to discuss the latest research and developments in the biomarker field. Other tracks of the summit include:

5th Oncology Biomarkers (Sept. 5th – 7th) | Inflammatory Biomarkers (Sept. 6th – 7th)

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Pradeep Nathan, Director of Neuroscience, GSK Featured at Neuro Biomarkers Meeting, September 6th-7th in Zurich

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: GTCbio.com 
626-256-6405 may.lee[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Huntington Study Group Ltd





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)